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ABSTRACT
Glioblastoma multiforme (GBM) carries a poor prognosis and continues to lack 
effective treatments. Glioblastoma stem cells (GSCs) drive tumor formation, invasion, 
and drug resistance and, as such, are the focus of studies to identify new therapies 
for disease control. Here, we identify the involvement of IKK and NF-κB signaling in 
the maintenance of GSCs. Inhibition of this pathway impairs self-renewal as analyzed 
in tumorsphere formation and GBM expansion as analyzed in brain slice culture. 
Interestingly, both the canonical and non-canonical branches of the NF-κB pathway 
are shown to contribute to this phenotype. One source of NF-κB activation in GBM 
involves the TGF-β/TAK1 signaling axis. Together, our results demonstrate a role 
for the NF-κB pathway in GSCs and provide a mechanistic basis for its potential as a 
therapeutic target in glioblastoma.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most 
common primary brain tumor in adults, but despite 
multimodal treatment combining surgery, radiation, and 
chemotherapy, the median survival for patients remains 
under 15 months [1]. Pathologically, GBM is described 
as a heterogeneous tumor type with high levels of 
angiogenesis and invasion [2]. Recent studies provide 
evidence for a population of cancer stem cells (CSCs) 
within GBM contributing to this heterogeneity [3, 4]. 
These cells (hereafter called GSCs) carry neural stem cell 
markers such as CD133, self-renew over serial passages, 
and differentiate into multiple lineages. As with tumor-
initiating cells described in other cancers [5-10], GSCs 
have been shown to be invasive and resistant to both 
radiation and chemotherapy [11-14]. As such, there is 
significant interest in understanding the biology of the 
GSC population to identify potential novel therapeutic 
targets to improve disease control.
NF-κB is a family of transcription factors consisting 
of five members: p65 (RelA), RelB, c-Rel, p105/p50, 
and p100/p52 that homo- and heterodimerize to regulate 
transcription of target genes. In the canonical pathway 
under basal conditions, p65-p50 dimers are bound to 
IκBα in the cytoplasm. Stimuli such as TNF-α or IL-1 
lead to activation of the IKK complex, which consists 
of two catalytic subunits, IKKα and IKKβ, as well as a 
scaffolding subunit, IKKγ or NEMO. IKK phosphorylates 
IκBα, leading to its ubiquitination and proteasomal 
degradation, which allows NF-κB to accumulate in the 
nucleus. The non-canonical pathway is activated by 
stimuli crucial for lymphoid development such as BAFF 
or CD40. Here, the precursor p100 acts as an IκB molecule 
bound to RelB. Upon activation, IKKα phosphorylates 
p100, leading to its cleavage to produce p52. The active 
RelB-p52 dimer can then regulate transcription of 
target genes [15, 16]. Originally identified for its role in 
inflammatory signaling, the NF-κB pathway has since 
been demonstrated to be activated in various forms of 
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cancer and is thought to contribute to the malignant 
phenotype through dysregulation of important biological 
processes such as proliferation, angiogenesis, apoptosis, 
and cell survival [16-19]. 
Within the nervous system, NF-κB is typically 
considered to be inactive, but activated in cases of injury 
or inflammation, consistent with its canonical function in 
other tissues [20, 21]. In normal neural stem cells (NSCs), 
TNFα has been shown to induce proliferation through 
NF-κB [22]. Kaus et al. [23] have shown that as NSCs 
acquire the ability to proliferate independent of exogenous 
growth factors, these cells demonstrate increased NF-κB 
activity. In GBM, NF-κB has been reported to regulate 
survival, invasion, and resistance to both radiation 
and chemotherapy [24-28]. PTEN deletion and EGFR 
amplification and/or mutation are two of the most 
common genetic alterations in GBM and both can lead to 
increased NF-κB activation [28, 29]. Additionally, TGF-β 
signaling has been demonstrated to contribute to GSC 
maintenance through the upregulation of LIF, Sox2, and 
Sox4 [30, 31]. While the TGF-β and NF-κB pathways are 
thought to antagonize each other in some settings, there 
is evidence of their cooperation within tumors, including 
GBM [32, 33]. Others have identified alterations in the 
NF-κB pathway itself, with a subset of GBMs harboring 
monoallelic NFKBIA (gene name for IκBα) deletions and 
others expressing high levels of miR-30e* which targets 
IκBα [34, 35]. Consistent with the involvement of NF-
κB signaling in GBM, recent work demonstrated that 
treatment with a NEMO-binding domain (NBD) peptide 
that blocks interactions between NEMO and IKKα/β 
slowed tumor growth in both a human glioma xenograft 
and a genetic mouse model of glioma [36]. 
NF-κB activity has been associated with CSCs in 
several cancer [37-42], and in GBM the NF-κB targets 
IL-6 and A20 have been shown to contribute to the 
maintenance of GSCs [43, 44]. When cells are grown in 
CSC-permissive conditions instead of monolayers, there 
is an upregulation of NF-κB activity as seen through 
p65 phosphorylation and target gene expression [45]. 
Other data suggest that inducing differentiation of GSCs 
increases NF-κB activity. However, NF-κB inhibition 
accelerates differentiation, suggesting a role for this 
pathway in maintaining the cells in a more stem-like state 
[46]. 
In this study, we sought to investigate the role 
of the NF-κB pathway in GSCs directly. We find that 
phosphorylation of the p65 (RelA) subunit of NF-κB is 
elevated in CD133+ GBM cells as compared to CD133- 
cells. Targeting NF-κB signaling either genetically or 
pharmacologically impairs self-renewal in primary 
tumorsphere assays and in limiting dilution assays. 
Interestingly, both canonical and non-canonical NF-κB 
pathways contribute to the GSC phenotype. Our results 
indicate that one source of NF-κB activation in GSCs is a 
TGF-β signaling pathway acting through TAK1. Using an 
ex vivo brain slice co-culture model, we show that NF-κB 
contributes to the growth and survival of tumorspheres. 
Our findings indicate that NF-κB signaling is a key 
therapeutic target controlling GSCs.
RESULTS
NF-κB is preferentially activated in CD133+ cells 
of GBM explants
Given that NF-κB is not highly active in normal 
brain tissue, we first compared the growth of normal 
neural stem cells and astrocytes to that of patient-derived 
GBM explant cultures. We treated cells with DMSO or 
with the selective IKKβ antagonist Compound A [47] 
daily for 5 days and measured cell viability by MTS 
assay (Figure 1A). Results demonstrate that growth was 
impaired in the GBM explant cultures by NF-κB inhibition 
but not in the normal neural stem cell or astrocyte cultures, 
suggesting that NF-κB inhibition preferentially targets 
tumor cells over normal brain cells. Since GBM was one 
of the first solid tumors in which CSCs were identified 
[3, 4] and based on our previous work implicating NF-
κB signaling in breast CSCs [39], we next asked if these 
findings could be explained by a role for NF-κB signaling 
in the growth of GSCs. To study the stem cell-like vs. 
non-stem cell-like subpopulation of glioblastoma cells, 
we isolated CD133+ and CD133- fractions from the 
human glioblastoma explant cultures using magnetic 
beads. Interestingly, the CD133+ cells exhibited elevated 
levels of p65 phosphorylation, consistent with increased or 
altered activity of the canonical NF-κB pathway (Figure 
1B).
Inhibition of NF-κB reduces tumorsphere 
formation
We next examined whether NF-κB was important 
in tumorsphere formation, which is an in vitro test 
for stem cell-like activity. After isolation, CD133+ 
cells were plated at a low density and allowed to form 
spheroids for one week prior to quantification. Daily 
treatment with Compound A abrogated tumorsphere 
formation completely. Importantly, a single treatment 
with Compound A at the beginning of the experiment was 
sufficient to reduce tumorsphere formation, suggesting 
that even transient loss of NF-κB activity could affect 
stem-like activity (Figure 2A, 2B). In order to further 
address the effects on self-renewal, primary tumorspheres 
from the first week of growth were dissociated, re-plated, 
and then subjected to the same treatments. Treatment 
with Compound A also reduced secondary tumorsphere 
formation, again consistent with a role for NF-κB activity 
in the stem-cell fraction (Figure 2C). Finally, we assayed 
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tumorsphere formation by using a limiting dilution assay 
with a range of cell concentrations from 1-100 cell(s)/well. 
For both 7030 and GBM6 CD133+ cells, treatment with 
Compound A significantly reduced the ability of GBM 
stem cells to form tumorspheres (Figure 2D, 2E).
In order to validate the on-target activity of 
Compound A in inhibiting IKK, we repeated these assays 
using siRNA-mediated knockdown of IKKβ and/or p65. 
Knockdown of either protein resulted in a decrease in p65 
phosphorylation, as well as a decrease in tumorsphere 
formation (Figure 3A-3C). The inhibitory effects of 
p65 knockdown were confirmed in the limiting dilution 
assay consistent with previous results (Figure 3D). Taken 
together, these results strongly implicate a role for the NF-
κB pathway in GSC propagation and self-renewal.
Multiple NF-κB subunits contribute to GSC 
maintenance
Up to this point, our studies have focused on the 
more highly studied canonical NF-κB pathway. We next 
sought to determine if the non-canonical NF-κB pathway, 
driven by a RelB-p52 dimer, could be contributing to GSC 
maintenance as well. Accordingly, GBM6 CD133+ cells 
were transfected with siRNAs targeting p65, p100/p52, 
or RelB. Each of these subunits produced a substantial 
decrease in tumorsphere formation in a limiting dilution 
assay (Figure 4A). Knockdown efficiency was confirmed 
through qPCR (Figure 4B). These results suggest that 
both the canonical and non-canonical NF-κB pathways 
contribute to GSC maintenance. 
Consistent with the literature, knockdown of p65 
resulted in decreased transcription of both RelB and 
p100 [48, 49]. We found that knockdown of p65 and 
IKKβ decreased expression of the non-canonical subunits 
at the protein level as well (Figure 4C). Interestingly, 
knockdown of IKKβ but not IKKα significantly decreased 
tumorsphere formation in a limiting dilution assay (Figure 
4D, 4E). Under normal culture conditions, no NIK 
expression was detected even with the addition of the 
proteasome inhibitor MG132. Perhaps not surprisingly, 
we did not see consistent results when attempting to 
knockdown NIK and assay tumorsphere formation (data 
Figure 1: NF-κB is preferentially activated in CD133+ glioblastoma stem cells. A. MTS assay using normal neural stem 
cells, astrocytes, or two GBM explants: 6969 and 7030. Cells were treated daily with DMSO or 5 μM Compound A and analyzed every 24 
hours for 96 hours. Data are represented as the mean ± s.d. and are representative of three independent experiments. B. Analysis of total 
cells, isolated CD133-, or CD133+ cells by immunoblot for phosphorylation of p65. Quantification of the immunoblots for the ratio of 
phospho-p65 to total p65 is: 7063 total: 1; CD133-: 0.23; CD133+: 1.77; 7030 total: 1; CD133-: 0.19; CD133+: 1.15.
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not shown). It is possible that the residual IKKα following 
siRNA knockdown is sufficient for p100 processing to p52 
and that a more complete knockout would reveal a larger 
effect for IKKα. Alternatively, p100 could be functioning 
in a separate role rather than simply being the precursor to 
p52, which is what is being observed in these experiments. 
These possibilities are further explored in the discussion. 
Nonetheless, these results suggest that transcriptional 
regulation of the non-canonical subunits (RelB and p100) 
by the canonical subunit (p65) could be a significant 
aspect of non-canonical pathway regulation in GSCs.
TAK1 activates the NF-κB pathway to promote 
GSC function
Next, we examined an upstream activator of the 
NF-κB pathway, transforming growth factor-β-activated 
kinase 1 (TAK1), which is known to activate the IKK 
complex following cytokine stimulation as well as in 
some oncogenic settings [50-54]. We first showed that 
use of two structurally distinct TAK1 inhibitors ((5Z)-
7-oxozeanol and NG-25) decreased the expression of an 
NF-κB luciferase reporter in both GBM explant cultures 
Figure 2: Pharmacological inhibition of the IKK/NF-κB pathway decreases tumorsphere formation. 7030 CD133+ 
cells plated for a tumorsphere assay and treated as indicated (DMSO or 5μM Compound A, once or daily). After one week of growth, 
tumorsphere formation was analyzed. A. Representative images of tumorsphere formation after daily treatment. B. Quantification of 
primary tumorspheres formed per well for two explants. Data are represented as mean ± SEM, ****p < 0.0001, ***p < 0.001, *p < 0.05 by 
t-test. C. Primary tumorspheres were dissociated, replated, and treated again as indicated. Secondary tumorsphere formation was quantified 
after another week of growth. Data are represented as mean ± SEM, ****p < 0.0001, ***p < 0.001, *p < 0.05 by t-test. D., E. Tumorsphere 
formation was measured through a limiting dilution assay with 7030 D. or GBM6 E. CD133+ cells plated at 100, 50, 20, 10, 5, or 1 cell(s)/
well and treated with DMSO or 5μM Compound A (7030: n = 48 wells/condition; p = 2.02x10-47; GBM6: n≥116wells/condition; p = 
2.23x10-11).
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(Figure 5A). In tumorsphere formation assays, treatment 
with either (5Z)-7-oxozeanol or NG-25 decreased 
tumorsphere formation in GBM 7030 CD133+ cells with 
a single treatment and to an even greater extent with daily 
treatment (Figure 5B). We then extended these studies in 
limiting dilution assays, finding that both siRNA against 
TAK1 and the TAK1 inhibitors resulted in significant 
decreases in tumorsphere formation (Figure 5C, 5D).
TGF-β is one source of NF-κB activation
As the cognate activator of TAK1 is transforming 
growth factor-β (TGF-β) itself, and as the TGF-β pathway 
has previously been implicated in regulating GBM CSCs 
[30, 31], we next investigated a potential link between 
TGF-β and NF-κB in the setting of GBM. Studies showed 
that treatment with exogenous TGF-β led to an increase 
in Smad phosphorylation (as expected) and in p65 
phosphorylation in GBM explant cultures (Figure 6A). 
Conversely, addition of a TGF-βR1 inhibitor (SB431542) 
led to a decrease in p65 phosphorylation (Figure 6B). 
Additionally, the TGF-βR1 inhibitor induced a small but 
consistent decrease in luciferase activity from an NF-κB 
reporter in GBM explant cultures (Figure 6C). Together, 
these results suggest an autocrine/paracrine role for TGF-β 
in maintaining NF-κB signaling in these GBM explant 
cultures. Use of the TGF-βR1 inhibitor in a tumorsphere 
assay leads to a significant decrease in tumorsphere 
formation in GBM6 CD133+ cells (Figure 6D). These 
results suggest that TGF-β can activate NF-κB signaling 
in these GBM explants. However, given the scale of these 
Figure 3: Genetic inhibition of the IKK/NF-κB pathway decreases tumorsphere formation. 7030 CD133+ cells were 
transfected with siRNA (control, p65, or IKKβ) and then plated for tumorsphere assays A. Quantification of tumorspheres formed per well 
after one week of growth. Data are represented as the mean ± SEM, ****p < 0.0001 by t-test. B. Transfected cells analyzed by immunoblot 
for p-p65, p65, IKKβ, and β-tubulin. C. Representative images of tumorsphere formation after daily treatment. D. Tumorsphere formation 
was measured through a limiting dilution assay with GBM6 CD133+ cells plated at 100, 50, 20, 10, 5, or 1 cell(s)/well following transfection 
with control or p65 siRNA (n≥70 wells; p = 1.76x10-6).
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changes, it is likely only one of several sources of NF-κB 
activation, consistent with the pleiotropic nature of this 
pathway. Similarly, given the more drastic effects seen in 
the tumorsphere assay with the TGF-βR1 inhibitor, it is 
likely that the TGF-β pathway is also mediating additional 
factors involved in GSC biology.
Inhibition of the IKK/NF-κB pathway decreases 
glioblastoma growth ex vivo
Finally, we sought to validate the in vitro studies 
in a more biologically relevant setting, turning to an ex 
vivo organotypic brain slice preparation which has been 
used previously [55, 56]. This methodology provided the 
opportunity for higher throughput analysis, as well as a 
level of longitudinal imaging not typically available in 
vivo. For these experiments, neonatal rat brain tissues 
were sectioned into 250 μm coronal slices, then plated 
on top of an agar medium as previously described [57]. 
GBM6-GFP spheres were then engrafted onto the upper 
surfaces of these these brain slice explants shortly after 
slicing. A first round of imaging was then completed 
within a few hours of plating to establish a baseline for 
GBM tumor growth these brain slices. The brain slices 
were then imaged daily for up to eight days and the GFP-
positive areas were quantified for each slice and on each 
day using ImageJ software. Representative images show 
that implanted GBM tumorspheres progressively grow and 
invade the surrounding brain tissues over the course of the 
experiment (Figure 7A).
To examine a role for NF-κB in GBM growth within 
these ex vivo orthotopic xenografts, GBM6-GFP cells 
Figure 4: Multiple NF-κB subunits contribute to tumorsphere formation. A. GBM6 CD133+ cells were transfected with 
siRNA control or targeting p65, RelB, or p100. Subsequently, cells were plated out for limiting dilution assay at 100, 50, 20, 10, 5, or 1 
cell(s)/well and scored for the presence or absence of tumorspheres following one week of growth (n≥95 wells/condition; p65 vs. control 
p = 2.26x10-5; RelB vs. control p = 6.44x10-5; p100 vs. control p = 3.82x10-5). B. Quantitative real-time PCR was performed to analyze 
expression of RELA, RELB, or NFKB2 in siRNA-transfected cells normalized to GUSB expression. C. Expression of canonical and non-
canonical NF-κB components was analyzed by immunoblot in 7030 CD133+ cells transfected with siRNA (control, p65, or IKKβ). D. 
GBM6 CD133+ cells were transfected with siRNA (control, IKKα, or IKKβ). Subsequently, cells were plated out for limiting dilution assay 
at 50, 20, 10, 5, 2, or 1 cell(s)/well and scored for the presence or absence of tumorspheres following one week of growth (n≥48 wells/
condition; IKKα vs. control p = 0.192; IKKβ vs. control p = 6.01x10-5). E. Quantitative real-time PCR was performed to analyze expression 
of CHUK and IKBKB in siRNA-transfected cells normalized to GUSB expression.
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were transfected with either control or p65 siRNA twenty-
four hours prior to tumorsphere formation and brain 
slice implantation. Quantification of tumorsphere cross-
sectional areas indicated that transfection with p65 siRNA 
significantly inhibited the growth rate of the implanted 
GBM tumorspheres over the course of the experiment 
(Figure 7B). Similarly, addition of the IKKβ inhibitor to 
the implanted brain slice cultures also led to significant 
inhibition of GBM tumorsphere growth (Figure 7C, 7D). 
DISCUSSION
As with many other tumor types, glioblastoma 
is characterized by a hierarchical organization of cells, 
including a subpopulation of so-called cancer stem cells 
(or tumor-initiating cells). These cells promote tumor 
initiation and recurrence, drive invasion and metastasis, 
and demonstrate increased resistance to radiation and 
chemotherapy [3, 4, 11-14]. It is crucial to investigate 
the signaling pathways responsible for these phenotypic 
differences from the bulk of the tumor, both to establish 
insight into mechanisms that promote these cells and 
to potentially identify therapeutic targets for disease 
control. In this study, we demonstrate the involvement 
of the IKK/NF-κB pathway in the function of GSCs. 
We identified a TGF-β/TAK1 axis as one source of NF-
κB activation in these cells. TAK1 is a well-established 
activator of IKK and there is a precedent for cooperation 
between the TGF-β and NF-κB pathways in GBM [32, 
33]. Nonetheless, it is likely that other sources for NF-κB 
activation exist, such as cytokines, which utilize TAK1 
as a mediator of NF-κB activation. Indeed, common 
genetic alterations seen in GBM (PTEN deletion, EGFR 
amplification and mutation, and monoallelic NFKBIA 
deletion) have all been connected to enhanced NF-κB 
activation [28, 34, 58-63]. Our data from the ex vivo co-
culture experiments show greater effects following IKK 
Figure 5: TAK1 activates the NF-κB pathway to promote glioblastoma stem cell function. A. 6969 or 7030 cells were 
transfected with 3x-κB luciferase reporter, treated with the indicated inhibitors for 24 hours, then harvest and analyzed for luciferase 
activity (n = 3; **p < 0.0001 by t-test, error bars represent SEM) B. Quantification of tumorsphere formation in GBM6 CD133+ cells 
following treatment with either (5Z)-7-oxozeaenol or NG25 either once or daily. Data are represented as the mean ± SEM, **p < 0.0001 by 
t-test. C. Limiting dilution assay with GBM6 CD133+ cells transfected with siRNA control or TAK1 (n = 72 wells/condition; p < 0.05). D. 
Limiting dilution assay following treatment of GBM6 CD133+ cells with structurally distinct TAK1 inhibitors: 2.5 μM (5Z)-7-oxozeaenol 
or 2 μM NG-25 (n≥90wells/condition; 5Z vs. DMSO p = 1.01x10-19, NG vs. DMSO p = 5.29x10-10).
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inhibition in the whole slice rather than just the cancer 
cells. Given the extensive number of cytokines and 
chemokines regulated by NF-κB, it is very likely that 
this pathway impacts the interactions between the tumor, 
microglia, and infiltrating immune cells, potentially 
related to the finding that GSCs promote tumor evasion via 
immunosuppression [64, 65]. Consistent with our studies 
overall, Verma and colleagues showed that treatment with 
an NBD peptide impaired tumor growth in both a human 
glioma xenograft and a genetic mouse model of glioma 
[36], focusing on inhibition of canonical NF-κB signaling 
through disruption of the IKK complex. Thus, the effects 
of IKK inhibition in GBM models may function, at least 
partly, at the level of GSCs. 
As a family of transcription factors, the NF-κB 
pathway is likely mediating a variety of downstream 
effects in GBM cells. We found that both the canonical 
and non-canonical branches contribute to GSC biology. 
Our results show larger effects of targeting RelB and 
p100 compared to IKKα, as well as decreased expression 
of the non-canonical subunits following knockdown of 
p65. One possibility is that since siRNA knockdown is 
incomplete, the remaining IKKα is still capable of driving 
sufficient processing of p100 into p52 and that use of a 
CRISPR knockout would produce a more substantial 
phenotype. Alternatively, since p52 is generated from 
p100 protein, knockdown at the gene level affects both 
p100 and p52 levels. Thus, we could actually be observing 
an independent effect of loss of p100 that is not dependent 
on IKKα for processing into the active p52 subunit. For 
example, a recent report demonstrated that p100 can 
interact with ERK2 and inhibit its nuclear localization 
[66], providing a precedent for p100-specific activities.
At this point, it is still unknown whether these two 
pathways are acting on common or separate targets. The 
dimerization and DNA binding patterns of NF-κB subunits 
remain complex areas of study [67-72]. The non-canonical 
pathway has been shown to have distinct functions in 
oncogenesis, such as driving growth and invasion of 
mesenchymal glioma and regulation of the mutant C250T 
Figure 6: TGF-β is one source of NF-κB activation in GBM. A. 6969 and GBM6 explants were stimulated with 10ng/mL TGF-β 
for 6 or 24 hours, then analyzed by immunoblotting for phosphorylation of Smad and p65. B. 6969 and GBM6 explants were treated with 
10 μM SB431542, a TGF-βR1 inhibitor, for 6 or 24 hours, then analyzed by immunoblotting for p65 phosphorylation. C. 6969 or 7030 cells 
were transfected with 3x-κB luciferase reporter and treated with DMSO or 10 μM SB431542 for 24 hours, then harvested and analyzed 
for luciferase activity (n = 3, **p < 0.0001, *p < 0.01 by t-test, error bars represent SEM). D. Quantification of tumorsphere formation 
in GBM6 CD133+ cells following treatment with 10 μM SB431542 either once or daily. Data are represented as the mean ± SEM, **p < 
0.0001 by t-test.
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TERT promoter [73, 74]. Antagonism of p53 through 
NF-κB regulation of Mdm2 expression has been well-
established and can contribute to chemotherapy resistance 
[75-77]. Additionally, NF-κB is known to regulate target 
genes related to several GSC functions including survival 
(BCL2, BCL2L1), invasion (IL6, IL8, CCL2, MMP2/3/9), 
and resistance to therapy (MGMT, TNFAIP3, TRADD) [78-
85]. Gene expression analysis showed NF-κB regulation 
of some of these targets, however neither the expression 
nor the NF-κB-dependency was limited to the CD133+ 
population of cells. It is likely that the effects on GSCs 
observed following NF-κB inhibition result from a 
combination of these and other genes. Given its central 
position in GSC signaling, the IKK/NF-κB pathway 
is proposed as a target for therapeutic intervention in 
glioblastoma. 
MATERIALS AND METHODS
Cell culture, CD133+ isolation, and reagents
The human glioblastoma explants (6969, 7030, 
7063, and GBM6) were obtained from UCSF and 
maintained in Neurobasal medium (Invitrogen), 
supplemented with B27 without Vitamin A, L-glutamine, 
20ng/mL EGF, 40ng/mL FGF, and penicillin/streptomycin. 
To dissociate tumorspheres, cells were incubated with 
Accutase (Sigma) in a 37°C water bath for 10 minutes, 
then plated as desired. To isolate CD133+ cells, cells were 
dissociated with Accutase and passed over a pre-separation 
filter to achieve single cell suspension. Dead cells were 
removed using the Dead Cell Removal Kit according 
to manufacturer’s instructions (Miltenyi). Remaining 
cells were incubated with CD133 magnetic microbeads 
(Miltenyi) for 30 minutes, resuspended in MACS buffer 
and passed over two LS columns consecutively. Non-
retained cells were saved for the CD133- fraction. After 
Figure 7: Inhibition of the IKK/NF-κB pathway decreases glioblastoma growth/survival ex vivo. A. Images of GFP+ GBM6 
cells following siRNA transfection and brain slice culture. B. Average percent change in GFP+ area over the course of the experiment (n 
= 14 for control, 13 for p65; p < 0.005 by linear regression; error bars represent SEM) C. Images of GFP+ GBM6 cells over the course of 
eight days of culture on brain slices following treatment with DMSO or Compound A. D. Average percent change in GFP+ area over the 
course of the experiment (n = 12; p < 0.01 by linear regression; error bars represent SEM)
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washing, the column was removed from the magnet and 
retained cells were expelled from the column, counted, 
and plated for experiments. Normal human astrocytes 
were a kind gift from Dr. Russell Pieper [86, 87] and 
were maintained in DMEM media with 10% FBS and 
1% penicillin/streptomycin. Neural stem cells (Millipore) 
were maintained in RenCell NSC maintenance media and 
grown on laminin-coated plates. 
3-(4,5-Dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium cellular proliferation assay
Cells were seeded at 2000 or 3000 cells per 
well in 96-well plates, then treated with DMSO or 
Compound A daily as indicated. At each time point, 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
compound (Promega) was added and absorbance was read 
at 490 nm on a Versamax Microplate Reader (Molecular 
Devices). 
Luciferase assay
Cells were transfected with 3x-κB luciferase reporter 
plasmid [88] using FuGENE HD (Promega). Six hours 
post-transfection, cells were separated into 12-well plates 
and treated in duplicate with inhibitors as indicated for 24 
hours. Cells were lysed in 150 μL of Passive Lysis Buffer, 
then 20 μL of lysate was used for analysis in triplicate 
using the Luciferase Assay System (Promega). Luciferase 
signal was read on a Synergy2 plate reader (Biotek), and 
then normalized to protein content of each well based on 
a Bradford assay.
Western blotting
Whole cell extracts were prepared by collecting 
cells, washing with cold PBS, then suspending in cold 
lysis buffer (1% NP-40, 20 mM Tris, 138 mM NaCl, 
2mM EDTA, 10% glycerol) on ice for 10 minutes, 
followed by 10 minutes of centrifugation to remove 
insoluble components. Protein was quantitated by 
Bradford assay (Biorad). Equal amounts of lysate (25-
50 μg) were separated by SDS-PAGE, transferred to 
nitrocellulose membranes, and blocked for 1 hour in 
5% milk. Membranes were incubated with primary 
antibody overnight at 4°C, then incubated with secondary 
antibody for 1 hour at room temperature and developed 
using ECL reagent (GE). Antibodies used were phospho-
Smad2/3 (S465, 467/S423, 425), phospho-p65 (S536), 
p65, IKKβ, RelB (Cell Signaling Technology), IKKα, 
p100/p52 (Millipore), TAK1 and β-tubulin (Santa Cruz 
Biotechnology).
siRNA transfection
Human siRNA targeting RELA (M-003533-02), 
RELB (M-004767-02), NFKB2 (M-003918-02), CHUK 
(M-003473-02), IKBKB (M-003503-03), MAP3K7 (M-
003790-06), or control #3 (D001201-03) was purchased 
from Thermo/Dharmafect. DharmaFECT reagent 1 
was used to transfect siRNA into cells according to the 
manufacturer’s instructions. Six hours post-transfection, 
the media was changed on the cells. Cells were harvested 
48-72 hours post-transfection for analysis by quantitative 
real-time PCR or Western blot.
Quantitative real-time PCR
RNA extracts were obtained from cells using the 
RNeasy Plus Kit (Qiagen). Two micrograms of RNA 
were reverse transcribed using random primers and 
MMLV reverse transcriptase (Invitrogen). Real-time PCR 
was performed using Taqman Gene Expression Assay 
primer-probe sets for GUSB (Hs99999908_m1), RELA 
(Hs00153294_m1), RELB (Hs00232399_m1), NFKB2 
(Hs01028901_g1), CHUK (Hs00989502_m1), and 
IKBKB (Hs00233287_m1) and relative quantification was 
determined using the ΔΔCt method.
Tumorsphere and limiting dilution assays
For tumorsphere assays, cells were dissociated into 
single cell suspension using Accutase. Cells were counted 
and plated at 100 cells per well in 24-well tissue culture 
plates. Cells were treated with inhibitors as indicated 
(once or daily for the duration of the experiment): 5 
μM Compound A, 2.5 μM (5Z)-7-oxozeanol (Tocris), 2 
μM NG25 (MedChem Express), and 10 μM SB431542 
(Tocris). Following one week of growth, tumorspheres 
were viewed on the microscope and quantified. For 
limiting dilution assays, cells were serially diluted to be 
plated at 100, 50, 20, 10, 5, 2 or 1 cell(s)/well in 96-well 
plates. After one week of growth, wells were scored for 
the presence or absence of spheres. Extreme limiting 
dilution analysis was performed as previously described 
[89], using software available at http://bioinf.wehi.edu.au/
software/elda/.
Brain slice explantation and tumorsphere 
implantation
Coronal brain slices (250 μm thick) from postnatal 
day 10 Sprague-Dawley rat pups of either sex (Charles 
River, Wilmington, MA) were prepared and explanted in 
organotypic culture as previously described [57]. Animals 
were sacrificed in accordance with NIH guidelines and 
under Duke IACUC approval and oversight. Briefly, brain 
Oncotarget69183www.impactjournals.com/oncotarget
tissues were sliced in ice-cold artificial cerebrospinal 
fluid and plated in interface configuration atop culture 
medium (Neurobasal A medium supplemented with 
15% heat-inactivated horse serum, 10 mM KCl, 10 mM 
HEPES, 100 U/ml penicillin/streptomycin, 1 mM sodium 
pyruvate, and 1 mM L-glutamine) semi-solidified in 
0.5% reagent-grade agarose in 12-well plates. Brain slice 
explants were incubated under 5% CO2 at 37 ºC for up to 
8 days as indicated. Compound A or DMSO-only vehicle 
was added to culture medium at the time of brain slice 
explantation. Small groups of GBM tumorspheres were 
implanted shortly thereafter by direct application to the 
upper surfaces of each brain slice. An epifluorescence 
stereomicroscope was used to obtain images through the 
course of experiments. ImageJ was used to quantify the 
area of GFP+ cells.
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